Talia Golan
YOU?
Author Swipe
View article: Supplementary Table S5 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Table S5 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Table S5 lists the antibodies used for CyTOF
View article: Supplementary Figure S1 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Figure S1 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Figure S1 demonstrates global metabolic changes in liver metabolism during early BC carcinogenesis
View article: Supplementary Table S4 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Table S4 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Table S4 lists the antibodies used for FACS
View article: Supplementary Table S2 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Table S2 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Table S2 lists the antibodies used for western blots
View article: Supplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting Open
In vivo growth kinetics and EVOC efficacy in acquired resistance model
View article: Supplementary table 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary table 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting Open
Clinical data of analyzed BRCA PDAC patients
View article: Supplementary Figure S3 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Figure S3 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Figure S3 shows that targeting the IL-6-pSTAT-HNF4a pathway preserves liver metabolism and restricts BC growth
View article: Supplementary Table S1 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Table S1 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Table S1 details clinical data of PDAC patients
View article: Supplementary Figure S2 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Figure S2 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Figure S2 demonstrates the infiltration of mature innate immune cells to the liver during breast carcinogenesis
View article: Supplementary Table S6 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Table S6 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Table S6 lists the genes regulated by HNF4a
View article: Supplementary Figure S5 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Figure S5 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Figure S5 demonstrate the significance of our liver score in predicting outcomes of BC and PDAC patients
View article: Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting Open
20 genes in DDR resistance
View article: Supplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting Open
Mechanisms of resistance in glBRCA PDAC
View article: Supplementary table 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary table 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i>–Associated Pancreatic Cancer in the Clinical and Preclinical Setting Open
In vivo, EVOC and clinical response
View article: Supplementary Figure S4 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Figure S4 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Figure S4 demonstrates similar transcriptional and metabolic changes following liver infiltration of immune cells to the liver of PDAC mice
View article: Supplementary Extended Data 1 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Extended Data 1 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Extended Data 1 describes the FACS gating startegy
View article: Supplementary Table S3 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis
Supplementary Table S3 from Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis Open
Supplementary Table S3 lists the primers used for qPCR
View article: Exploring pancreatic variability in BRCA carriers vs. Non-Carriers: A diffusion tensor MRI study
Exploring pancreatic variability in BRCA carriers vs. Non-Carriers: A diffusion tensor MRI study Open
DT-MRI effectively measures diffusion coefficients and IVIM contributions in the pancreas. No significant differences were found between high-risk individuals and controls, therefore, the method supports adjunct, bias-free use in future pa…
View article: Pancreatic Cancer with Liver Oligometastases—Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection
Pancreatic Cancer with Liver Oligometastases—Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection Open
Background: Pancreatic adenocarcinoma (PDAC) with liver oligometastases (LOM) presents a therapeutic challenge, with optimal management strategies remaining uncertain. This study evaluates the long-term outcomes, patterns of disease progre…
View article: Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Therapy
Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Therapy Open
View article: Supplementary Data 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Supplementary Data 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Table S1, Figure S1, Figure S2
View article: Figure 2 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Figure 2 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Best percentage change from baseline in target lesions per RECIST version 1.1 in (A) arm 1 (IT MK-2118 monotherapy), (B) arm 2 (IT MK-2118 plus IV pembrolizumab), and (C) arm 4 (SC MK-2118 plus IV pembrolizumab).
View article: Table 3 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Table 3 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Most common AEs and all immune-mediated AEs (safety population).
View article: Data from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Data from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Purpose:We evaluated the noncyclic dinucleotide stimulator of IFN genes agonist MK-2118 ± pembrolizumab in participants with advanced solid tumors or lymphomas.Patients and Methods:This first-in-human study (NCT03249792) enrolled participa…
View article: Supplementary Data 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Supplementary Data 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Table S1, Figure S1, Figure S2
View article: Figure 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Figure 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Arithmetic mean plasma concentration–time profiles of MK-2118 during cycle 1 following either IT (monotherapy and combination therapy with IV pembrolizumab) or SC (combination therapy with IV pembrolizumab) administration. MK-2118 concentr…
View article: Figure 3 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Figure 3 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Geometric mean fold changes in (A) blood RNA, (B) IP-10, (C) IFNγ, (D) IL6, and (E) CRP in participants in arms 1, 2, and 4. Data are 6 hours postdose vs. predose for blood RNA and time point vs. predose …
View article: Table 2 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Table 2 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Summary of DLTs (DLT-evaluable population)a.
View article: Table 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Table 1 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas Open
Demographics and baseline characteristics (safety population).
View article: 47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers
47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers Open